CLEVELAND CLINIC HOSPITAL
1. Target Overview & Investment Thesis
CLEVELAND CLINIC HOSPITAL is a 1326-bed large academic medical center in CUYAHOGA, OH with $6.38B in net patient revenue and a -17.7% operating margin. The hospital serves a payer mix of 22.5% Medicare, 5.2% Medicaid, and 72.3% commercial.
Thesis: Undervalued. Our ML models identify $469.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -17.7% to -10.3% (+736bps).
| Net Revenue HCRIS | $6.38B |
| Current EBITDA COMPUTED | $-1.13B |
| Operating Margin COMPUTED | -17.7% |
| Occupancy HCRIS | 75.9% |
| Revenue / Bed COMPUTED | $4.8M |
| Net-to-Gross HCRIS | 30.7% |
| Distress Probability ML | 41.1% |
2. Market Context & Competitive Position
OH has 235 Medicare-certified hospitals with a median operating margin of -0.3%. The target's margin of -17.7% places it below the state median. Among 130 size-comparable peers (663-2652 beds), the median margin is -5.4%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (663-2652), prioritizing same-state peers. 130 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| CLEVELAND CLINIC HOSPITAL (Target) | OH | 1326 | $6.38B | -17.7% |
| NYU LANGONE HOSPITALS | NY | 1618 | $7.24B | -7.8% |
| VANDERBILT UNIVERSITY MEDICAL | TN | 1084 | $5.44B | -15.9% |
| UCSF MEDICAL CENTER | CA | 834 | $5.44B | -5.4% |
| UT MD ANDERSON CANCER CENTER | TX | 721 | $4.90B | -0.8% |
| UNIV OF MI HOSPITALS & HLTH CT | MI | 951 | $4.62B | -1.4% |
| CEDARS-SINAI MEDICAL CENTER | CA | 908 | $3.92B | -5.5% |
| INDIANA UNIVERSITY HEALTH | IN | 1269 | $3.58B | -38.4% |
| MASSACHUSETTS GENERAL HOSPITAL | MA | 997 | $3.50B | -44.9% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $469.5M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $134.0M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $127.6M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $126.3M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $77.6M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $4.1M | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-1.13B |
| + RCM Uplift | +$469.5M |
| Pro Forma EBITDA | $-659.1M |
| Current Margin | -17.7% |
| Pro Forma Margin | -10.3% |
| WC Released (1x) | $244.7M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-1.74B | $-2.75B | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-1.74B | $-3.59B | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-1.56B | $-2.60B | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-1.56B | $-3.30B | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-1.91B | $-4.53B | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-1.91B | $-5.61B | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 130 hospitals with 663-2652 beds
- Same-state prioritization (n=7)
- Comp margins: P25=-15.7% / P50=-5.4% / P75=4.1%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.